Skip to main content

Table 3 Efficacy of antiviral prophylaxis in HBsAg-positive patients

From: Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition

EventsNo. (%) of patientsDifference between groups, % (95% CI)OR (95% CI)P valuea
Total (n = 114)Patients without antiviral prophylaxis (n = 29)Patients with antiviral prophylaxis (n = 85)
Hepatitis
 All grades35 (30.7)8 (27.6)27 (31.8)4.2 (−16.01–20.83)0.82 (0.32–2.08)0.674
 Grade 3/410 (8.8)4 (13.8)6 (7.1)6.7 (−4.50–23.89)2.10 (0.55–8.07)0.467
 HBV reactivation6 (5.3)5 (17.2)1 (1.2)16.0 (5.05–33.33)17.50 (1.95–157.07)0.004
 HBV-related hepatitis5 (4.4)4 (13.8)1 (1.2)12.6 (2.80–29.40)13.44 (1.44–152.79)0.019
 Immunotherapy disruptionb11 (9.6)4 (13.8)7 (8.2)5.6 (−5.78–22.88)1.78 (0.48–6.60)0.609
  1. aDetermined using the χ2 test
  2. bIncluded ten cases of immunotherapy delay and one case of discontinuation
  3. Abbreviations: HBsAg hepatitis B surface antigen, HBV hepatitis B virus, OR odds ratio, CI confidence interval